Faron Pharmaceuticals scraps Lago Kapital liquidity deal as natural trading volumes pick up

Faron Pharmaceuticals, the Finnish clinical-stage immunotherapy group, has terminated its liquidity provision agreement with Lago Kapital, citing improved natural trading activity in its shares — a notable signal of the dual-listed biotech's gradually strengthening profile in the public markets.

The Turku-based company, listed on London's AIM market and on Nasdaq First North in Helsinki, said on Wednesday that the agreement with Helsinki-based brokerage Lago Kapital Oy would end on 5 June 2026. Faron said the current liquidity of its shares was "sufficient without additional liquidity providers", a judgement that reflects the change in the trading dynamics around the stock following months of speculative interest in its lead asset and the recent emergence of US specialist investor Heights Capital Management as a 25 per cent shareholder through a combination of equity and convertible debt.

Liquidity provision agreements — under which a designated market maker quotes both bid and ask prices for a stock to ensure continuous trading and tighter spreads — have historically been a common feature of small-cap European equity markets, particularly for companies dual-listed across exchanges with thinner natural order flow. Their termination is typically read as a sign that a company has built sufficient organic trading volume to allow market dynamics to function without intermediation, and is usually framed by management as a positive operational milestone rather than a defensive move.

For Faron, the timing reflects a more visible position in the public markets. The recent Heights Capital disclosure under UK transparency rules made plain that an institutional investor of meaningful size now controls a significant slug of both the company's equity and its convertible debt, with the potential for further conversion-driven trading activity ahead of the bonds' February 2027 and February 2028 maturities. That, alongside the broader investor focus on Faron's lead immunotherapy programmes, has translated into improved share turnover and tighter trading conditions.

The decision is broadly cost-neutral for the business, freeing up the modest fees and operational requirements associated with maintaining a formal liquidity arrangement. More significantly, it places Faron alongside a slowly growing cohort of small-cap European biotechs whose shares have moved beyond the early-stage need for designated market-making support — a transition that, while incremental in financial terms, is often viewed by the buy-side as a marker of corporate maturation.

For shareholders, the termination is unlikely to prove materially disruptive in the near term, given the recent rise in trading volumes. The longer-term test will be whether Faron's natural liquidity holds up across the inevitable cycle of clinical and regulatory catalysts that will move the stock — and whether the company's broader profile in the institutional investor base continues to deepen as the underlying business advances.